National Health (Pharmaceutical Benefits Therapeutic Groups) Amendment Determination 2013 (No. 1) (No. PB 6 of 2013) (Cth)
PB 6 of 2013
National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2013 (No. 1)1
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 84AG(1) of the National Health Act 1953.
Dated 25 March 2013
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
Name of Determination
(1) This Determination is the National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2013 (No. 1).
(2) This Determination may also be cited as PB 6 of 2013.
Commencement
This Determination commences on 1 April 2013.
3 Amendments to PB 1 of 2010
Schedule 1 amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 (PB 1 of 2010).
Schedule 1 Amendments
[1] Section 4 Definitions
omit:
Bisphosphonates osteoporosis group means the oral Bisphosphonates osteoporosis group.
Bisphosphonates Paget disease group means the oral Bisphosphonates Paget disease of bone group.
pharmaceutical benefits instrument means an instrument made under subsection 85 (2A) of the Act, as in force from time to time.
[2] Section 6 Drugs in Therapeutic Groups
omit:
‘and subsection 84AG(2) of the Act’
[3] Section 6 Drugs in Therapeutic Groups
omit:
‘, in the circumstances (if any) mentioned in the Part’
[4] Schedule 1, after
Part 7 Statins-HP group
| Item | Listed drug |
| 1 | Atorvastatin |
| 2 | Rosuvastatin |
insert:
Part 8 Venlafaxine group
| Item | Listed drug |
| 1 | Desvenlafaxine |
| 2 | Venlafaxine |
Note
1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See
0
0
0